Clinical phase III open-label study of oral garenoxacin in patients with otorhinolaryngological infection

Japanese Journal of Chemotherapy

Volumn 55, Issue SUPPL. 1, 2007, Pages 194-205

  Baba, Shunkichi ^a   Suzuki, Kenji ^b   Yamanaka, Noboru ^c   Yajin, Koji ^d  

^a NAGOYA CITY UNIV MEDICAL SCHOOL   (Japan)

^b FUJITA HEALTH UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^c WAKAYAMA MEDICAL UNIVERSITY   (Japan)

^d HIROSHIMA UNIV SCHOOL OF MEDICINE   (Japan)

Author keywords

Des fluoro(6) quinolone; Garenoxacin; Otorhinolaryngological infection; T 3811MEa; Tissue penetration

Indexed keywords

ALANINE AMINOTRANSFERASE; AMYLASE; ASPARTATE AMINOTRANSFERASE; BILIRUBIN; BILIRUBIN GLUCURONIDE; CREATINE KINASE; GAMMA GLUTAMYLTRANSFERASE; GARENOXACIN; LACTATE DEHYDROGENASE;

ABDOMINAL PAIN; ADULT; AGED; ARTICLE; CLINICAL TRIAL; DIARRHEA; DROWSINESS; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG PENETRATION; DRUG SAFETY; EAR NOSE THROAT DISEASE; ERADICATION THERAPY; FEMALE; FLATULENCE; GASTROINTESTINAL TOXICITY; GLUCOSE BLOOD LEVEL; GLUCOSURIA; HUMAN; LARYNGITIS; LEUKOCYTE COUNT; LOOSE FECES; MALE; MINIMUM INHIBITORY CONCENTRATION; NAUSEA; NONHUMAN; OTITIS MEDIA; PARANASAL SINUSITIS; PHARYNGITIS; PHASE 3 CLINICAL TRIAL; PROTEINURIA; RASH; SIDE EFFECT; STOMACH DISCOMFORT; TONSILLITIS; UPPER ABDOMINAL PAIN;

EID: 35348984646     PISSN: 13407007     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (11)

1. Japanese source.
2. Japanese source.
3. Japanese source.
4. Clinical and Laboratory Standards Institute. Performance Standards for Antimicrobial Susceptibility Test; M100-S15. CLSI, 2005
5. Japanese source.
6. Japanese source.
7. Japanese source.
8. Japanese source.
9. Japanese source.
10. Japanese source.
11. Japanese source.